Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression.
Prostate cancer (PC) is the second leading cause of cancer deaths in men in America and Western Europe. Epidemiological studies suggest that prostate cancer incidences increased in last few years in Asian. The causes or consequences of increasing trend of prostate cancer incidence are not completely known. Emerging evidences suggest that among the many risk factors, inflammation is the major risk factor for developing prostate cancer and its progression to metastasis. It is proposed that exposure to environmental factors such as infectious agents, dietary agents and saturated lipids leads to injury of the prostate due to chronic inflammation and regenerative risk factor lesions referred to as proliferative inflammatory atrophy (PIA). These phenomena predominantly control by a number of proinflammatory macro molecules such as chemokines, and their receptors. Some recent studies suggest that many of these pro-inflammatory chemokines and their receptors are the products of protooncogenes in many cancers including that of the prostate. This review will focus on the current biology of chemokines and chemokine receptors in prostate cancer. An understanding of this axis may enable researchers to develop targeted strategies for prostate cancer.
Singh
Rajendra K
RK
Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Sudhakar
Akulapalli
A
Lokeshwar
Bal L
BL
Expert Rev Endocrinol Metab. 2009 Sep 1;4(5):417-422
20228873
Clin Cancer Res. 2005 Jun 1;11(11):4117-27
15930347
Zhonghua Nan Ke Xue. 2010 Jan;16(1):40-3
20180403
Cancer Res. 2004 Aug 1;64(15):5489-95
15289359
J Immunol. 2000 Apr 1;164(7):3465-70
10725697
Arthritis Rheum. 2002 Oct;46(10):2730-41
12384933
J Immunol. 1999 May 15;162(10):5671-5
10229797
Neuro Oncol. 2005 Apr;7(2):122-33
15831231
Cytokine Growth Factor Rev. 2002 Apr;13(2):143-54
11900990
Mol Cancer. 2009 Jul 31;8:57
19646263
Cancer Res. 2002 Feb 15;62(4):1093-102
11861388
Int J Cancer. 2007 Oct 1;121(7):1571-8
17450530
Nat Rev Immunol. 2002 Mar;2(3):175-84
11913068
Urology. 2001 Apr;57(4 Suppl 1):39-45
11295593
Prostate. 2009 Dec 1;69(16):1774-80
19670242
Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67
17828470
J Exp Med. 2006 Sep 4;203(9):2201-13
16940167
Cancer Res. 2005 Nov 1;65(21):9891-8
16267013
Future Oncol. 2008 Oct;4(5):637-45
18922121
J Exp Med. 1999 Dec 20;190(12):1755-68
10601351
J Am Geriatr Soc. 1996 Aug;44(8):934-7
8708303
Lancet Oncol. 2008 May;9(5):445-52
18424233
J Immunol. 1999 Aug 15;163(4):2017-22
10438939
Front Biosci. 2008 May 01;13:4595-604
18508531
J Urol. 2005 Jan;173(1):10-20
15592017
Exp Cell Res. 2006 Jan 15;312(2):184-97
16297907
Front Biosci. 2006 May 01;11:1388-413
16368524
Cancer Res. 2007 Jul 15;67(14):6854-62
17638896
Am J Pathol. 1999 May;154(5):1503-12
10329603
Nat Immunol. 2001 Feb;2(2):108-15
11175802
Adv Urol. 2009;:327945
19730753
J Natl Cancer Inst. 1999 Nov 17;91(22):1950-6
10564679
Am J Physiol Cell Physiol. 2002 May;282(5):C947-70
11940508
Int J Cancer. 2007 Oct 1;121(7):1424-32
17551921
Clin Cancer Res. 2007 Sep 1;13(17):5056-62
17785557
PLoS One. 2009;4(5):e5562
19440546
Curr Drug Targets Immune Endocr Metabol Disord. 2004 Dec;4(4):343-61
15578986
Nat Rev Cancer. 2005 Jan;5(1):21-8
15630412
Clin Exp Metastasis. 2008;25(4):345-56
17891505
Br J Urol. 1996 Jun;77(6):851-5
8705220
Nat Rev Cancer. 2007 Apr;7(4):256-69
17384581
J Oncol. 2010;2010:361836
20169138
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24
17925537
J Dermatol Sci. 2004 Nov;36(2):71-8
15519136
Eur Urol. 2007 Oct;52(4):964-72
17618043
Br J Cancer. 2006 Jan 16;94(1):101-7
16404363
J Biol Chem. 2000 Mar 31;275(13):9550-6
10734104
Stem Cells. 2001;19(5):388-96
11553847
Cancer. 2006 Aug 1;107(3):620-30
16802287
Cancer Sci. 2005 Jun;96(6):317-22
15958053
PLoS One. 2009 Aug 19;4(8):e6695
19690611
Cancer Res. 2008 Feb 1;68(3):927-36
18245496
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Urol. 1995 Oct;154(4):1420-5
7658548
BJU Int. 2007 Oct;100(4):733-7
17662075
Clin Prostate Cancer. 2005 Jun;4(1):24-30
15992458
Prostate. 2002 Mar 1;50(4):203-15
11870798
PLoS One. 2010 Jan 15;5(1):e8736
20090948
J Natl Cancer Inst. 2005 Oct 19;97(20):1525-32
16234566
Cancer. 2007 Jun 15;109(12):2392-404
17503430
J Sex Med. 2010 Jan;7(1 Pt 2):389-413
20092446
Urology. 1997 Jun;49(6):875-80
9187694
Annu Rev Immunol. 2000;18:217-42
10837058
Antimicrob Agents Chemother. 2000 Jun;44(6):1667-73
10817726
N Engl J Med. 2009 Mar 26;360(13):1320-8
19297566
J Clin Oncol. 2001 May 1;19(9):2517-26
11331331
Cancer. 2002 Jul 15;95(2):287-95
12124828
Cancer Biol Ther. 2008 Nov;7(11):1849-51
18981717
J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67
15367568
Prostate. 2005 Jun 15;64(1):40-9
15651067
J Biol Chem. 1998 Jun 26;273(26):16551-4
9632725
Semin Cancer Biol. 2009 Apr;19(2):68-75
19084599
Cancer. 2004 Nov 15;101(10 Suppl):2371-490
15495199
Science. 1999 Dec 10;286(5447):2098-102
10617422
Immunity. 2000 Feb;12(2):121-7
10714678
Semin Cancer Biol. 2004 Jun;14(3):181-5
15246053
Endocr Relat Cancer. 2009 Sep;16(3):663-73
19556286
J Exp Med. 1998 Mar 16;187(6):875-83
9500790
J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1253-62
15385732
Cancer Res. 2002 Mar 15;62(6):1832-7
11912162